➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
McKesson
Dow
Colorcon
Boehringer Ingelheim

Last Updated: January 18, 2021

DrugPatentWatch Database Preview

Patent: 9,132,118

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,132,118
Title:Taxane analogs for the treatment of brain cancer
Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
Inventor(s): McChesney; James D. (Etta, MS), Tapolsky; Gilles (Louisville, KY), Emerson; David L. (Longmont, CO), Marshall; John (Washington, DC), Kurman; Michael (Upper Saddle River, NJ), Modiano; Manuel (Tucson, AZ)
Assignee: Tapestry Pharmaceuticals, Inc. (Atlanta, GA)
Application Number:13/785,753
Patent Claims:see list of patent claims

Details for Patent 9,132,118

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Tapestry Pharmaceuticals, Inc. (Atlanta, GA) 2027-02-28 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Tapestry Pharmaceuticals, Inc. (Atlanta, GA) 2027-02-28 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,132,118

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2008042138   Start Trial
World Intellectual Property Organization (WIPO) 2008106621   Start Trial
World Intellectual Property Organization (WIPO) 2008109360   Start Trial
United States of America 10143677   Start Trial
United States of America 2008091996   Start Trial
United States of America 2011318334   Start Trial
United States of America 2013253044   Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Colorcon
Boehringer Ingelheim
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.